STEMCELL HOLDINGS, INC. Financial Statements (2025 and earlier)
Company Profile
| Business Address |
OMOTESANDO HELENE CLINIC 3-18-17-6F MINAMIAOYAMA, MINATO-KU, TOKYO, 107-0062 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 677 - Blank Checks (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 9/30/2018 MRQ | 12/31/2017 | 12/31/2016 | |||
|---|---|---|---|---|---|
| ASSETS | |||||
| Current Assets | |||||
| Cash, cash equivalents, and short-term investments | 4,484 | 2,647 | |||
| Cash and cash equivalents | 4,484 | 2,647 | |||
| Receivables | 177 | ||||
| Other undisclosed current assets | 616 | 52 | |||
| Total current assets: | 5,277 | 2,699 | |||
| Noncurrent Assets | |||||
| Property, plant and equipment | 1,034 | 530 | |||
| Other undisclosed noncurrent assets | (988) | ||||
| Total noncurrent assets: | 46 | 530 | |||
| Other undisclosed assets | 1,095 | ||||
| TOTAL ASSETS: | 6,418 | 3,229 | |||
| LIABILITIES AND EQUITY | |||||
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities, including: | 279 | 574 | |||
| Taxes payable | 550 | 1,188 | |||
| Accrued liabilities | 1,782 | 106 | |||
| Other undisclosed accounts payable and accrued liabilities | (2,053) | (720) | |||
| Other undisclosed current liabilities | 2,332 | 1,294 | |||
| Total current liabilities: | 2,610 | 1,868 | |||
| Noncurrent Liabilities | |||||
| Total liabilities: | 2,610 | 1,868 | |||
| Equity | |||||
| Equity, attributable to parent | 3,808 | 1,361 | |||
| Common stock | 3 | 3 | |||
| Additional paid in capital | 65 | 65 | |||
| Accumulated other comprehensive loss | (67) | (104) | |||
| Retained earnings | 3,807 | 1,397 | |||
| Total equity: | 3,808 | 1,361 | |||
| TOTAL LIABILITIES AND EQUITY: | 6,418 | 3,229 | |||
Income Statement (P&L) ($ in thousands)
| 9/30/2018 TTM | 12/31/2017 | 12/31/2016 | ||
|---|---|---|---|---|
| Revenues | 6,180 | 3,346 | ||
| Revenue, net | ✕ | 6,180 | 3,339 | |
| Cost of revenue | (1,186) | (369) | ||
| Other undisclosed gross profit | (7) | |||
| Gross profit: | 4,994 | 2,970 | ||
| Operating expenses | (1,394) | (318) | ||
| Operating income: | 3,600 | 2,652 | ||
| Nonoperating income (expense) | 74 | (101) | ||
| Gain, foreign currency transaction, before tax | 37 | 3 | ||
| Conversion gains and losses on foreign investments | 37 | (104) | ||
| Income from continuing operations before income taxes: | 3,674 | 2,551 | ||
| Income tax expense | (1,189) | (1,253) | ||
| Income from continuing operations: | 2,485 | 1,298 | ||
| Income before gain (loss) on sale of properties: | 2,485 | 1,298 | ||
| Other undisclosed net income (loss) | (76) | 104 | ||
| Net income available to common stockholders, diluted: | 2,410 | 1,402 | ||
Comprehensive Income ($ in thousands)
| 9/30/2018 TTM | 12/31/2017 | 12/31/2016 | ||
|---|---|---|---|---|
| Net income: | 2,410 | 1,402 | ||
| Comprehensive income, net of tax, attributable to parent: | 2,410 | 1,402 | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.